Clinical Trial Update: Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ravidasvir plus Danoprevir/r for 12 weeks in treatment-naive non-cirrhotic genotype 1 chronic hepatitis C patients shows completed stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Danoprevir (danoprevir)
• Ravidasvir (ravidasvir)
• Ritonavir-boosted danoprevir (danoprevir)

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2020-10-22